What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Surgery
- Cancer
Jacques P. Brown focuses on Osteoporosis, Internal medicine, Surgery, Bone density and Bone remodeling.
His work deals with themes such as Physical therapy and Urology, which intersect with Osteoporosis.
His Internal medicine research includes elements of Endocrinology and Oncology.
His research integrates issues of Risedronic acid, Teriparatide, Bone disease and Intensive care medicine in his study of Surgery.
His Bone density study incorporates themes from Vitamin D and neurology, Tomography and Bone strength.
Jacques P. Brown has included themes like Transcription factor, Bone resorption, Molecular biology, Placebo and Sequestosome-1 Protein in his Bone remodeling study.
His most cited work include:
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis: A Randomized Controlled Trial (2169 citations)
- 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary (1449 citations)
- Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis (1032 citations)
What are the main themes of his work throughout his whole career to date?
His scientific interests lie mostly in Osteoporosis, Internal medicine, Denosumab, Surgery and Bone mineral.
His Osteoporosis study integrates concerns from other disciplines, such as Physical therapy, Bone remodeling and Urology.
His Urology research incorporates elements of Alendronic acid and Zoledronic acid.
His research on Internal medicine frequently connects to adjacent areas such as Endocrinology.
Within one scientific family, he focuses on topics pertaining to Postmenopausal women under Denosumab, and may sometimes address concerns connected to Pediatrics.
Jacques P. Brown interconnects Risedronic acid, Bisphosphonate, Placebo, Etidronic acid and Bone disease in the investigation of issues within Surgery.
He most often published in these fields:
- Osteoporosis (56.82%)
- Internal medicine (37.01%)
- Denosumab (24.03%)
What were the highlights of his more recent work (between 2013-2021)?
- Osteoporosis (56.82%)
- Denosumab (24.03%)
- Internal medicine (37.01%)
In recent papers he was focusing on the following fields of study:
Osteoporosis, Denosumab, Internal medicine, Surgery and Urology are his primary areas of study.
His Osteoporosis study combines topics in areas such as Bone remodeling and Cohort.
His work carried out in the field of Denosumab brings together such families of science as Incidence, Cortical bone, Postmenopausal women, Total hip replacement and Placebo.
Jacques P. Brown works mostly in the field of Internal medicine, limiting it down to topics relating to Endocrinology and, in certain cases, Downregulation and upregulation.
Jacques P. Brown has researched Surgery in several fields, including Teriparatide, Quantitative computed tomography, Bisphosphonate-associated osteonecrosis of the jaw and Intensive care medicine.
His Bone density research focuses on Hip fracture and how it relates to FRAX and Pediatrics.
Between 2013 and 2021, his most popular works were:
- Romosozumab in Postmenopausal Women with Low Bone Mineral Density (723 citations)
- Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus (563 citations)
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension (299 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Surgery
- Cancer
His main research concerns Osteoporosis, Denosumab, Surgery, Internal medicine and Femoral neck.
His study in Osteoporosis is interdisciplinary in nature, drawing from both Placebo, Bone remodeling and Urology.
The concepts of his Denosumab study are interwoven with issues in Bone mineral, Bone formation and Cohort.
His biological study spans a wide range of topics, including Postmenopausal women, Bisphosphonate-associated osteonecrosis of the jaw and Intensive care medicine.
His study ties his expertise on Endocrinology together with the subject of Internal medicine.
His studies deal with areas such as Romosozumab, Fracture risk, Incidence, Adverse effect and Diaphyseal fracture as well as Femoral neck.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
